Arbutus Biopharma Sues Pfizer, BioNTech Over Alleged Patent Infringement
By Will Feuer
Arbutus Biopharma Corp. and its licensee Genevant Sciences have filed a patent-infringement lawsuit against Pfizer Inc. and BioNTech SE related to the latter's Covid-19 vaccine.
Arbutus Biopharma, a clinical-stage biopharmaceutical company, said Tuesday that the patents relate to nucleic acid-lipid particles and their composition, manufacture, delivery and methods of use.
The company said Genevant is seeking compensation for Pfizer's and BioNTech's unlicensed use of its patented lipid nanoparticle delivery technologies in their Covid-19 vaccine.
"We believe that Pfizer and BioNTech could not have created and manufactured effective vaccines at such an unprecedented speed without the existing, proven and patented LNP technologies owned by Arbutus and licensed to Genevant," Arbutus Biopharma Chief Executive William Collier said.
Representatives for Pfizer and BioNTech didn't immediately return a request for comment.
Write to Will Feuer at Will.Feuer@wsj.com
(END) Dow Jones Newswires
April 04, 2023 08:21 ET (12:21 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Boeing Stock a Buy, a Sell, or Fairly Valued?
-
The 10 Best Companies to Invest in Now
-
Paramount Earnings: CEO Has Gone, For-Sale Sign Is Up; Good Results Would’ve Been Nice to Learn
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024